History full circle: 'Novel' sympathomimetics in supplements.

Since the banning of ephedrine in over-the-counter nutritional supplements a decade ago, a plethora of untested and/or unsafe sympathomimetic stimulants have taken its place. This paper argues that these 'novel' stimulants in supplements recapitulate the work of synthetic chemists at commercial pharmaceutical firms during the 1930s and 1940s, all seeking substitutes for recently successful products based on ephedrine and amphetamine. Copyright © 2015 John Wiley & Sons, Ltd.

Supplement use by UK-based British Army soldiers in training.

The use of supplements is widespread at all levels of civilian sport and a prevalence of 60-90 % is reported among high-performance UK athletes, including juniors. The prevalence of supplement use among UK-based British Army personnel is not known. The aim of the present study was to establish the point prevalence of supplement use in UK-based British Army soldiers under training (SuTs) and associated staff. A cross-sectional anonymous survey was carried out in 3168 British Army SuTs and soldiers, equating to 3·1 % of regular Army strength, based at eleven Phase 1, 2 and 3 UK Army training sites. Overall, 38 % of the respondents reported current use of supplements, but prevalence varied according to the course attended by the respondents. The number of different supplements used was 4·7 (sd 2·9). Supplements most commonly used were protein bars, powders and drinks (66 %), isotonic carbohydrate-electrolyte sports drinks (49 %), creatine (38 %), recovery sports drinks (35 %), multivitamins (31 %) and vitamin C (25 %). A small proportion of respondents reported the use of amphetamines and similar compounds (1·6 %), cocaine (0·8 %), anabolic androgenic steroids (1·1 %), growth hormone (2·0 %), and other anabolic agents, e.g. testosterone (4·2 %). Logistic regression modelling indicated that, for current users, younger age, being female, smoking and undergoing Officer Cadet training were associated with greater supplement use. This is the first study to investigate the prevalence of dietary and training supplement use in UK-based British military personnel. Self-administration of a wide range of supplements is reported by British military personnel in training, which is at least as great as that reported by those on deployment, and has implications for Defence policy and educational needs.

Comparative study between n-6, trans and n-3 fatty acids on repeated amphetamine exposure: a possible factor for the development of mania.

In the last decades, foods rich in omega-3 (ω-3) fatty acids (FA) have been replaced by omega-6 (ω-6) and trans FA, which are found in processed foods. The influence of ω-6 (soybean oil--SO), trans (hydrogenated vegetable fat--HVF) and ω-3 (fish oil--FO) fatty acids on locomotor and oxidative stress (OS) parameters were studied in an animal model of mania. Rats orally fed with SO, HVF and FO for 8 weeks received daily injections of amphetamine (AMPH--4 mg/kg/mL-ip) for the last week of oral supplementation. HVF induced hyperactivity, increased the protein carbonyl levels in the cortex and decreased the mitochondrial viability in cortex and striatum. AMPH-treatment increased the locomotion and decreased the mitochondrial viability in all groups, but its neurotoxicity was higher in the HVF group. Similarly, AMPH administration increased the protein carbonyl levels in striatum and cortex of HVF-supplemented rats. AMPH reduced the vitamin-C plasmatic levels of SO and HVF-fed rats, whereas no change was observed in the FO group. Our findings suggest that trans fatty acids increased the oxidative damage per se and exacerbated the AMPH-induced effects. The impact of trans fatty acids consumption on neuronal diseases and its consequences in brain functions must be further evaluated.

Boltushka: a homemade amphetamine-type stimulant and HIV risk in Odessa, Ukraine.

BACKGROUND: Homemade amphetamine-type stimulants (ATSs) have been reported in Russia and Eastern Europe for decades. Recipes differ geographically and over time producing differing active ingredients. Vint and jeff (active ingredients methamphetamine and methcathinone, respectively) are two such homemade ATSs originally produced from over-the-counter cold medications and household chemicals. METHODS: During a Rapid Policy Assessment and Responses (RPAR) project in Odessa, Ukraine, researchers found use of boltushka, a novel homemade ATS. Fourteen supplemental qualitative interviews were conducted, including ten interviews with boltushka injectors and four interviews with pharmacists. We report patterns of boltushka use among local injection drug users (IDUs) as well as the role of laws, regulations, and current pharmacy practices. RESULTS: Legal restrictions on over-the-counter cold medicines in Ukraine led to products containing phenylpropanolamine (PPA), which oxidised with KMnO(4) (potassium permanganate), produces a weak ATS, cathinone, called boltushka. Boltushka's ingredients are easily available in pharmacies or on the black market. IDUs reported a mean age at first use of 16 years old (range 12-21). While published data are scant, anecdotal evidence reported here include amphetamine-like effects on energy and appetite, binging patterns of use, and some reports of shaking and other neurological damage consistent with earlier reports from exposure to KMnO(4). Users reported sharing syringes and other non-sterile injection practices. No users reported specific treatment or prevention programs for boltushka users. CONCLUSIONS: Although Ukrainian government regulations have limited access to precursor chemicals, IDUs have continued to make and use boltushka. The actual extent and demographics of boltushka use are unknown. Besides risk of bloodborne disease, the health effects of injected homemade ATSs and their constituent chemicals are poorly documented. Interventions beyond available harm reduction efforts may be required. Education/treatment specific to boltushka users and screening for other physical harms are critical interventions.

Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.

Behavioral and psychological symptoms of dementia (BPSD) are commonly seen in patients with Alzheimer's disease (AD) and other forms of senile dementia. BPSD have a serious impact on the quality of life of dementia patients, as well as their caregivers. However, an effective drug therapy for BPSD has not been established. Recently, the traditional Japanese medicine Yokukansan (YKS, Yi-gan san in Chinese) has been reported to improve BPSD in a randomized, single-blind, placebo-controlled study. Moreover, abnormalities of the serotonin (5-HT) system such as 5-HT2A receptors have been reported to be associated with BPSD of AD patients. In the present study, we investigated the effect of YKS on head-twitch response induced by 2,5-dimethoxy-4-iodoamphetamine (DOI, 5 mg/kg, i.p.) in mice, a behavioral response that is mediated, in part, by 5-HT2A receptors. Acute treatment with YKS (100 and 300 mg/kg, p.o.) had no effect on the DOI-induced head-twitch response, whilst 14 days repeated treatment with YKS (300 mg/kg, p.o.) significantly inhibited this response. Moreover, repeated treatment with YKS (300 mg/kg, p.o.) decreased expression of 5-HT2A receptors in the prefrontal cortex, which is part of the circuitry mediating the head-twitch response. These findings suggest that the inhibition of DOI-induced head-twitch response by YKS may be mediated, in part, by altered expression of 5-HT2A receptors in the prefrontal cortex, which suggests the involvement of the 5-HT system in psychopharmacological effects of YKS.

The effects of serotonin agonists on the hypothalamic regulation of sexual receptivity in Syrian hamsters.

One brain region that has been implicated in the regulation of lordosis is the medial preoptic-anterior hypothalamic continuum (MPOA-AH). Previous studies have suggested that this zone may be part of the circuit mediating the effects of serotonin (5-HT) on sexual receptivity. In the present experiments, we investigated the role of 5-HT(1a/7) and 5-HT(2) receptor subtypes in the MPOA-AH in the control of lordosis. In two experiments, either 5-HT(1a/7) or 5-HT(2) agonists were injected unilaterally into the MPOA-AH of ovariectomized, hormonally primed female hamsters. In the first experiment, microinjections of the 5-HT(1a/7) agonist 8-hydroxy-2,9-(di-n-propylamino)tetralin resulted in an attenuation of the lordosis posture by causing a decrease in the mean lordosis duration and an increase in the number of lordosis episodes over the entire testing period. In the second experiment, microinjections of the 5-HT(2b/2c) agonist m-chlorophenylpiperazine did not result in any changes in sexual receptivity. However, microinjections of the 5-HT(2) agonist (2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl facilitated lordosis by increasing the mean lordosis duration and decreasing the number of lordosis episodes in the first 5 min of the testing period. These data indicate that serotonin may act in the MPOA-AH via 5-HT(1a/7) receptors to attenuate and 5-HT(2) receptors to facilitate sexual receptivity.

Differential regional zif268 messenger RNA expression in an escalating dose/binge model of amphetamine-induced psychosis.

Amphetamine-induced psychosis is most often associated with a high-dose multiple binge pattern of stimulant abuse. To simulate these conditions in rats, we used an escalating dose/binge administration paradigm. Animals were pretreated with escalating doses of amphetamine (1.0-8.0mg/kg) over four days, then exposed to nine daily binges (8.0mg/kg every 2h; four injections/day). Other animals received either multiple injections of saline, saline followed by acute amphetamine (8.0mg/kg) or single daily injections of amphetamine (8.0mg/kg) in parallel with the escalating dose/binge treatment. One hour after the last injection, all animals were decapitated and regional brain activation patterns were assessed using in situ hybridization with antisense probes for zif268. Acute amphetamine resulted in a significant elevation of zif268 messenger RNA in both the nucleus accumbens and dorsal striatum. However, whereas after single daily amphetamine treatment this index was no longer elevated above control levels in the dorsal striatum, multiple binge exposures were required for the nucleus accumbens to return to baseline. Agranular insular cortex and medial olfactory tubercle zif268 messenger RNA expression was also markedly increased after acute amphetamine treatment but, unlike the nucleus accumbens and dorsal striatum, this increase was not significantly attenuated by either single daily injection or multiple binge treatment. Zif268 messenger RNA expression in the lateral nucleus of the amygdala also remained elevated above baseline after binge treatment. The possible relationships of these changes in zif268 messenger RNA regional expression patterns to the development of psychosis in high-dose stimulant abusers are discussed.

5-HT1A and muscarinic acetylcholine receptors jointly regulate passive avoidance behavior.

The present study was designed to investigate the effects of combined stimulation of 5-HT1A or 5-HT2 receptors and blockade of muscarinic acetylcholine receptors on passive avoidance behavior. Administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2 receptor agonist, impaired passive avoidance acquisition (pre-training injections) and consolidation (post-training injections) performance. Ketanserin, a 5-HT2 receptor antagonist, blocked the performance-impairing effect of DOI on passive avoidance consolidation. Interestingly, 5-HT receptor agonists may affect passive avoidance consolidation only during the immediate post-training period, as passive avoidance testing performance was not modulated by 8-OH-DPAT or DOI injected 30 min after the training trial. Furthermore, passive avoidance retention (pre-testing injections) performance was impaired only by the highest dose of 8-OH-DPAT, and DOI had no effect on passive avoidance retention. Next, the effects of combined 5-HT and acetylcholine receptor manipulations on passive avoidance behavior were studied. The effects on passive avoidance behavior of a combination of subthreshold doses of scopolamine, a muscarinic acetylcholine receptor antagonist, and 8-OH-DPAT were compared to those of a single high dose of scopolamine. A combination of small doses of scopolamine and 8-OH-DPAT impaired acquisition and consolidation of passive avoidance performance, but a single high dose of scopolamine impaired only acquisition performance. The small dose of 8-OH-DPAT also aggravated medial septal lesion-induced passive avoidance acquisition and consolidation failure. The combination of small doses of scopolamine and DOI had no effect on passive avoidance behavior. Peripherally acting scopolamine methylbromide alone or in combination with 8-OH-DPAT had no effect on passive avoidance performance. Motor activity in a swimming pool was altered by single and combined drug treatments; high doses of 8-OH-DPAT and scopolamine, and the combination of small doses of 8-OH-DPAT + scopolamine increased speed of swimming. Medial septum-lesioning also increased speed of swimming but the speed was not increased further by 8-OH-DPAT. The present data suggest that behavioral defect caused by hypostimulation of muscarinic acetylcholine receptors is aggravated by concurrent 5-HT1A receptor stimulation.

Evaluation of prevalence of "doping" among Italian athletes.

To evaluate knowledge of, attitudes to, and use of illegal drugs and other forms of "doping" in sport 1015 Italian athletes and 216 coaches, doctors, and managers (technicians) were interviewed after selection on a quota basis. Overall, 30% of athletes, managers, and coaches and 21% of doctors indicated that athletic performance can be enhanced by drugs or other doping practices. Over 10% of athletes indicated a frequent use of amphetamines or anabolic steroids at national or international level, fewer athletes mentioning blood doping (7%) and beta-blockers (2%) or other classes of drugs. These proportions were 2-3 times higher for occasional use than for frequent use. Estimates by managers and coaches were much the same as those of athletes when allowance was made for larger random variation. 62% of athletes who acknowledged doping reported pressure to do so from coaches and managers. According to over 70% of athletes access to illegal substances was not difficult. Both athletes and technicians awarded higher scores to risk than to efficacy for any substance, although 42-67% of athletes and technicians regarded amphetamines and anabolic steroids as efficacious. 82% wanted stricter controls not only during competitions but also during training.

Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol.

The effects on feeding of perifornical hypothalamic injection of catecholamines, amphetamines and mazindol were examined in hungry rats. In pargyline-pretreated subjects, both dopamine and epinephrine significantly suppressed food intake, at doses as low as 31 ng for dopamine and 150 ng for epinephrine (the latter injected with an alpha-adrenoceptor blocker). This effect was reliably strengthened by inhibiting catecholamine deamination or presynaptic catecholamine uptake. Perifornical injections of amphetamine, mazindol, methamphetamine, and phenmetrazine also suppressed feeding. The magnitude of this effect in individual animals was positively correlated with the effect produced by catecholamine agonists. Moreover, this effect of mazindol was partially antagonized by perifornical injection of dopaminergic and beta-adrenoceptor blockers. The effects of amphetamine and epinephrine were abolished by these drugs, while dopamine's effect was selectively inhibited by the dopaminergic antagonist. Serotonergic antagonists produced no change. These findings lend support to the hypothesis that perifornical hypothalamic catecholamine neurons, through dopaminergic receptors and beta-adrenoceptors, are involved in inhibiting feeding behavior, as well as in mediating the anorexic action of the amphetamines and mazindol.